NASDAQ:AGLE Aeglea BioTherapeutics - AGLE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aeglea BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.33 +0.01 (+3.13%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.31▼$0.3350-Day Range$0.30▼$0.6152-Week Range$0.30▼$3.17Volume87,438 shsAverage Volume229,228 shsMarket Capitalization$21.58 millionP/E RatioN/ADividend YieldN/APrice Target$1.88 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aeglea BioTherapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside468.2% Upside$1.88 Price TargetShort InterestHealthy0.86% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.76) to ($0.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.42 out of 5 starsMedical Sector205th out of 1,005 stocksPharmaceutical Preparations Industry86th out of 486 stocks 3.3 Analyst's Opinion Consensus RatingAeglea BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.88, Aeglea BioTherapeutics has a forecasted upside of 468.2% from its current price of $0.33.Amount of Analyst CoverageAeglea BioTherapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.86% of the outstanding shares of Aeglea BioTherapeutics have been sold short.Short Interest Ratio / Days to CoverAeglea BioTherapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aeglea BioTherapeutics has recently decreased by 23.15%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAeglea BioTherapeutics does not currently pay a dividend.Dividend GrowthAeglea BioTherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AGLE. Previous Next 2.7 News and Social Media Coverage News SentimentAeglea BioTherapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aeglea BioTherapeutics this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aeglea BioTherapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.50% of the stock of Aeglea BioTherapeutics is held by insiders.Percentage Held by Institutions78.01% of the stock of Aeglea BioTherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Aeglea BioTherapeutics are expected to grow in the coming year, from ($0.76) to ($0.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aeglea BioTherapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aeglea BioTherapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAeglea BioTherapeutics has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aeglea BioTherapeutics (NASDAQ:AGLE) StockAeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.Read More Receive AGLE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AGLE Stock News HeadlinesMarch 21, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Aeglea BioTherapeutics (NASDAQ:AGLE)March 17, 2023 | finance.yahoo.comAeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 26, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.March 7, 2023 | msn.comAeglea BioTherapeutics's Return On Capital Employed InsightsMarch 3, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aeglea Biotherapeutics (AGLE) and Argenx Se (ARGX)March 2, 2023 | markets.businessinsider.comLifeSci Capital Keeps Their Buy Rating on Aeglea Biotherapeutics (AGLE)March 2, 2023 | finanznachrichten.deAeglea BioTherapeutics, Inc.: Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program UpdatesMarch 2, 2023 | finance.yahoo.comAeglea Biotherapeutics (AGLE) Reports Q4 Loss, Lags Revenue EstimatesMarch 26, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.March 2, 2023 | finance.yahoo.comAeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program UpdatesFebruary 12, 2023 | finance.yahoo.comAeglea BioTherapeutics, Inc. (NASDAQ:AGLE) insiders placed bullish bets worth US$695k in the last 12 monthsJanuary 6, 2023 | nasdaq.comAeglea Names Cortney Caudill Chief Product Officer; To Halt Work On CystinuriaJanuary 6, 2023 | finance.yahoo.comAeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational EfficiencyDecember 14, 2022 | finance.yahoo.comAeglea (AGLE) Moves to Buy: Rationale Behind the UpgradeDecember 3, 2022 | finance.yahoo.comAeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 30, 2022 | finance.yahoo.comAeglea Nosedives After Clinical Update On Investigational Candidate For Rare Metabolism DiseaseNovember 4, 2022 | msn.comRecap: Aeglea BioTherapeutics Q3 EarningsNovember 3, 2022 | finance.yahoo.comAeglea Biotherapeutics (AGLE) Reports Q3 Loss, Misses Revenue EstimatesNovember 3, 2022 | finance.yahoo.comAeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program UpdatesNovember 2, 2022 | msn.comWhy Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From YesterdayOctober 19, 2022 | finance.yahoo.comAeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase's Potential Role in TreatmentOctober 4, 2022 | seekingalpha.comAeglea stock dips as FDA places partial hold on enrolling under 18 patients in metabolic disorder trialOctober 4, 2022 | finance.yahoo.comFDA Puts Partial Hold On Aeglea's Rare Disorder Trial In Pediatric PatientsOctober 4, 2022 | finance.yahoo.comAeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria ProgramAugust 29, 2022 | finance.yahoo.comAeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022August 27, 2022 | finance.yahoo.comTrade Alert: Marcio De'Souza At Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), Has Just Spent US$50k Buying A Small Number of SharesAugust 24, 2022 | finance.yahoo.comAeglea Bio Feels FDA Refusal Pinch, Cuts Workforce, Shifts Pipeline FocusSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AGLE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AGLE Company Calendar Last Earnings11/04/2021Today3/26/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGLE CUSIPN/A CIK1636282 Webwww.aegleabio.com Phone(512) 942-2935Fax512-872-5121Employees101Year FoundedN/APrice Target and Rating Average Stock Price Forecast$1.88 High Stock Price Forecast$3.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+468.2%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,820,000.00 Net Margins-3,598.75% Pretax Margin-3,604.59% Return on Equity-127.15% Return on Assets-95.09% Debt Debt-to-Equity RatioN/A Current Ratio4.25 Quick Ratio4.25 Sales & Book Value Annual Sales$2.33 million Price / Sales9.26 Cash FlowN/A Price / Cash FlowN/A Book Value$0.82 per share Price / Book0.40Miscellaneous Outstanding Shares65,390,000Free Float61,144,000Market Cap$21.58 million OptionableOptionable Beta1.71 Key ExecutivesJeffrey M. GoldbergPresident, Chief Executive Officer & DirectorJonathan D. AlspaughChief Financial & Accounting OfficerScott W. RowlinsonVice President-ResearchLinda NeumanChief Medical OfficerCortney CaudillChief Product OfficerKey CompetitorsZynerba PharmaceuticalsNASDAQ:ZYNENightHawk BiosciencesNYSE:NHWKPaxMedicaNASDAQ:PXMDEquilliumNASDAQ:EQEdesa BiotechNASDAQ:EDSAView All CompetitorsInsiders & InstitutionsNantahala Capital Management LLCBought 900,524 shares on 2/15/2023Ownership: 7.497%Millennium Management LLCBought 2,316,807 shares on 2/15/2023Ownership: 5.091%Sphera Funds Management LTD.Bought 440,837 shares on 2/15/2023Ownership: 0.717%Morgan StanleySold 87,797 shares on 2/15/2023Ownership: 0.131%Two Sigma Investments LPBought 290,049 shares on 2/14/2023Ownership: 0.640%View All Insider TransactionsView All Institutional Transactions AGLE Stock - Frequently Asked Questions Should I buy or sell Aeglea BioTherapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AGLE shares. View AGLE analyst ratings or view top-rated stocks. What is Aeglea BioTherapeutics' stock price forecast for 2023? 5 brokerages have issued 12 month target prices for Aeglea BioTherapeutics' stock. Their AGLE share price forecasts range from $1.00 to $3.00. On average, they predict the company's share price to reach $1.88 in the next twelve months. This suggests a possible upside of 468.2% from the stock's current price. View analysts price targets for AGLE or view top-rated stocks among Wall Street analysts. How have AGLE shares performed in 2023? Aeglea BioTherapeutics' stock was trading at $0.4499 at the beginning of the year. Since then, AGLE stock has decreased by 26.7% and is now trading at $0.33. View the best growth stocks for 2023 here. When is Aeglea BioTherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our AGLE earnings forecast. How were Aeglea BioTherapeutics' earnings last quarter? Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) issued its earnings results on Thursday, November, 4th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.03. The biotechnology company earned $1.40 million during the quarter, compared to analyst estimates of $1.38 million. Aeglea BioTherapeutics had a negative trailing twelve-month return on equity of 127.15% and a negative net margin of 3,598.75%. What is Anthony Quinn's approval rating as Aeglea BioTherapeutics' CEO? 3 employees have rated Aeglea BioTherapeutics Chief Executive Officer Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among the company's employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Aeglea BioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aeglea BioTherapeutics investors own include Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Kura Oncology (KURA), Aduro Biotech (ADRO), Axsome Therapeutics (AXSM), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX) and Dicerna Pharmaceuticals (DRNA). When did Aeglea BioTherapeutics IPO? (AGLE) raised $60 million in an IPO on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager. What is Aeglea BioTherapeutics' stock symbol? Aeglea BioTherapeutics trades on the NASDAQ under the ticker symbol "AGLE." Who are Aeglea BioTherapeutics' major shareholders? Aeglea BioTherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Nantahala Capital Management LLC (7.50%), Millennium Management LLC (5.09%), Pura Vida Investments LLC (1.70%), Geode Capital Management LLC (0.98%), Sphera Funds Management LTD. (0.72%) and Two Sigma Investments LP (0.64%). Insiders that own company stock include Anthony G Quinn, Anthony G Quinn, Armen Shanafelt, Jonathan Alspaugh, Jr Michael Conick Hanley and Marcio Souza. View institutional ownership trends. How do I buy shares of Aeglea BioTherapeutics? Shares of AGLE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aeglea BioTherapeutics' stock price today? One share of AGLE stock can currently be purchased for approximately $0.33. How much money does Aeglea BioTherapeutics make? Aeglea BioTherapeutics (NASDAQ:AGLE) has a market capitalization of $21.58 million and generates $2.33 million in revenue each year. The biotechnology company earns $-83,820,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. How many employees does Aeglea BioTherapeutics have? The company employs 101 workers across the globe. How can I contact Aeglea BioTherapeutics? Aeglea BioTherapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The official website for the company is www.aegleabio.com. The biotechnology company can be reached via phone at (512) 942-2935, via email at investors@aegleabio.com, or via fax at 512-872-5121. This page (NASDAQ:AGLE) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.